HRS 9231
Alternative Names: HRS-9231Latest Information Update: 19 Aug 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Contrast media; Imaging agents
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Vascular disorders
Most Recent Events
- 29 Jul 2024 Atridia plans a phase-0 trial for Vascular disorders (In volunteers, Diagnosis) in Australia (IV), (NCT06519981)
- 12 Apr 2024 Jiangsu Hengrui Medicine Co. plans a phase-I trial for Vascular disorders (Diagnosis) in China (IV), (CTR20241752)
- 12 Apr 2024 Preclinical trials in Vascular disorders (Diagnosis) in China (IV)